Pain Modulation after Oromucosal Cannabinoid Spray (SATIVEX(®)) in Patients with Multiple Sclerosis: A Study with Quantitative Sensory Testing and Laser-Evoked Potentials

Background. Delta-9-tetrahydrocannabinol (THC)/cannabidiol (CBD) (nabiximols or Sativex(®)) is an oromucosal spray formulation containing THC and CBD at an approximately 1:1 fixed ratio. Its administration for the treatment of pain in patients with multiple sclerosis (MS) has been established. MS pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Turri, Mara, Teatini, Francesco, Donato, Francesco, Zanette, Giampietro, Tugnoli, Valeria, Deotto, Luciano, Bonetti, Bruno, Squintani, Giovanna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6163235/
https://www.ncbi.nlm.nih.gov/pubmed/29933552
http://dx.doi.org/10.3390/medicines5030059

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6163235/
https://www.ncbi.nlm.nih.gov/pubmed/29933552
http://dx.doi.org/10.3390/medicines5030059

Ejemplares similares